Full-Time

Director – Customer Insights Lead

Animal Health

Posted on 9/23/2025

Deadline 10/6/25
Merck

Merck

10,001+ employees

Pharmaceutical company developing medicines and vaccines

Compensation Overview

$187k - $294.4k/yr

+ Annual Bonus + Long-term Incentive

H1B Sponsorship Available

Linden, NJ, USA

Remote

This is a remote position that can be based in multiple regions.

Category
Business & Strategy (3)
, ,
Requirements
  • 10+ years of experience in large technology and/or biopharma corporate organizations.
  • Positive attitude, excellent interpersonal skills, and proven ability to navigate highly matrixed organizations.
  • Exceptional attention to detail and commercial instinct.
  • Veterinary training and technical background in livestock are preferred.
  • Ability to travel 30 to 40% of the time.
  • Fluency in English is required; ability to speak additional languages is desired.
Responsibilities
  • Champion a customer-centric culture and lead a global initiative to elevate understanding of customer needs and market opportunities.
  • Lead, design, and launch four or more CABs comprised of select, highly influential, key account customers, defining membership, objectives, and engagement strategies.
  • Work closely with Regional Vice-Presidents and Country Managers to identify key customers and opinion leaders across key global markets with significant market potential.
  • Lead the process of recruiting key customers to join CABs and to become close partners during the new product development process.
  • Facilitate annual CAB in-person meetings for each business segment as well as frequent virtual workshops and roundtable discussions to engage customers and ensure the capture of rich and diverse perspectives.
  • Build strong relationships with CAB executive members throughout this process so they evolve organically into product champions that promote our solutions to expand penetration and maximize sales outcomes.
  • Distill CAB discussions into strategic recommendations and share outcomes with MAH Executive Leadership Team, R&D, and commercial teams.
  • Continuously evaluate and improve CAB effectiveness through feedback, performance metrics, and best practices.
  • Create and maintain a dynamic customer needs repository, ensuring the organization remains aware and responsive to evolving market demands.
  • Develop comprehensive R&D portfolio management strategy for Technology Solutions, ensuring roadmaps across species and business segments align with customer needs and strategic priorities.
  • Lead multi-disciplinary teams towards creating clearly articulated customer value propositions for our technology solutions and correlate these to revenue projections for our innovative products and R&D pipeline.
  • Build comprehensive analytical models to quantify market potentials and revenue projections within an evidence-based framework and ensure that framework is leveraged consistently across R&D projects.
  • Lead governance forums and facilitate transparent, data-driven decision-making for pipeline investments, resource allocation, and program prioritization.
  • Connect TDCI strategies to the overall MAH strategic framework and work closely with the 'Tech Adoption Strategic Pillar' Lead to make sure our metrics are aligned with business goals and 5YP targets as set by the MAH’s Executive Vice-President and Leadership Team.
  • Coordinate New Product Launch activities across species and business segments ensuring strategy execution includes CAB executive members as Product Champions.
  • Partner with TDCI Leads to develop go-to-market strategies that effectively communicate product’s customer value proposition to maximize financial outcomes.
  • Establish clear connections between TDCI roadmap projects across species and business segments and 5YP targets to drive sales budgeting processes.
  • Build strong rapport with Regional and Local Operations to effectively activate and execute joint commercial initiatives towards maximizing sales performance of our current portfolio.
Desired Qualifications
  • Proven leadership presence required to ensure customer needs become central to strategy and roadmap decisions at the highest governance levels.
  • Skilled in translating customer voice into strategic action and driving organizational alignment.
  • Effective working within cross-disciplinary teams and managing competing priorities; ability to lead without direct authority.
  • Strong ability to interpret complex data and derive actionable insights; proficiency in financial modelling and scenario planning.
  • Adept at tailoring messages to diverse audiences, from technical teams to executive leadership.
  • Proven capability to cultivate trust and rapport with external customers and internal teams.
  • Experienced in developing go-to-market strategies focused on business and commercial solutions.
  • Comfortable navigating ambiguity and adapting to rapidly changing environments.
  • Capable of navigating diverse cultural norms and values to effectively lead global teams.

Merck is a global healthcare company that develops medicines, vaccines, and animal health products. It advances long-term health by conducting research and development to create new treatments for diseases such as cardiovascular disease, diabetes, and cancer, then brings these medicines to patients, healthcare professionals, and institutions worldwide. The company’s products work by undergoing scientific discovery, clinical testing, and regulatory approval before being manufactured and sold or distributed through patient assistance programs. What sets Merck apart is its large, diversified portfolio across human medicines, vaccines, and animal health, along with a strong emphasis on R&D, global reach, and support services like Merck Connect and Merck Manuals that provide professional resources. Merck’s goal is to tackle major health threats by applying science to discover and deliver therapies that improve patient outcomes and public health across the globe.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kenilworth, Illinois

Founded

1891

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approves IDVYNSO HIV therapy launching post-May 11, 2026.
  • Keytruda Qlex adds $128 million Q1 sales with administration advantages.
  • Peenya facility expands for filtration, targeting $14.06B market by 2035.

What critics are saying

  • Keytruda patent expires 2028, biosimilars slash $8B quarterly sales 70%.
  • Gardasil trial starts July 27, 2026, erodes trust amid RFK Jr. involvement.
  • Gardasil sales drop 19% Q1 2026 from Chinese competition permanently.

What makes Merck unique

  • Keytruda generates $8 billion in Q1 2026 sales, up 12% year-over-year.
  • Winrevair surges 88% to $525 million in Q1 2026 across US, Japan, Europe.
  • Cidara Therapeutics $9.2 billion acquisition bolsters antifungal pipeline.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Hybrid Work Options

Company News

Castlefield
Apr 27th, 2026
Engagement update with Merck & co on animal testing and packaging.

Engagement update with Merck & co on animal testing and packaging. By Ffion Spencer * Share * April 27/04/2026, 12:00 AM As part of its ongoing efforts to improve performance across key environmental, social, transparency and governance (E.S.T.) metrics, Castlefield Partners Limited recently engaged with US pharmaceutical company Merck & co., held in the castlefield thoughtful World Equity Fund, to discuss its approach to animal testing, the use of animal-derived ingredients, and packaging practices. At a recent External Advisory Committee meeting, the committee highlighted increasing numbers of animals being used in animal testing across the pharmaceutical sector. Around the same time, Castlefield Partners Limited also received a client query relating to the use of animal derived ingredients in pharmaceutical products. This engagement therefore focused on three material topics for the pharmaceutical industry: animal testing, the use of animal derived ingredients in products, and plastic use. In its initial response, Merck explained that it makes extensive use of non animal research methods, including in vitro techniques, computer modelling and advanced imaging, prior to or instead of animal studies. The company shared that approximately 96% of its research animals are rodents and confirmed that it maintains detailed records on animal use across species, purpose and site, including research carried out by third party organisations on Merck's behalf. As Merck has confirmed that it maintains this data internally, Castlefield Partners Limited has encouraged greater transparency through public disclosure. Castlefield Partners Limited also encouraged the company to consider setting reduction targets on this topic. While this response suggests a baseline level of governance and oversight, Castlefield Partners Limited believe there is scope for further progress. Castlefield Partners Limited has followed up and are awaiting further written responses.Castlefield Partners Limited note that some peers, including French pharmaceutical company Sanofi, which is also held in the World Equity Fund, publish the total number of animals used for scientific research on an annual basis. As Merck has confirmed that it maintains this data internally, Castlefield Partners Limited has encouraged greater transparency through public disclosure. Castlefield Partners Limited also encouraged the company to consider setting reduction targets on this topic. On animal derived ingredients, Merck highlighted the use of specialised tools to identify potential non animal alternatives, indicating consideration of reduction and substitution where scientifically feasible. On plastics, the company shared that it has developed a long term roadmap aimed at reducing the environmental impact of its packaging, suggesting an acknowledgement of plastics as a material environmental issue within its operations. Overall, while Merck provided high level information across all three topics, the most detailed discussion related to animal testing, reflecting its materiality to the sector. Outcome: Its engagement confirmed that Merck has a level of baseline governance on these topics. However, further engagement with the company is required, particularly in relation to transparency and disclosure on the number of animals used in scientific testing. Information is accurate as at 20.04.2026. Opinions constitute the fund manager's judgement as of this date and are subject to change without warning. The officers, employees and agents of CIP may have positions in any securities mentioned herein. This material may not be distributed, published or reproduced in whole or in part. With investment, capital is at risk.

Yahoo Finance
Apr 14th, 2026
Merck keeps Keytruda cancer drug prices high as single dose reaches $163K

Merck's cancer drug Keytruda has become a pricing flashpoint in US healthcare, with a single 400mg dose billed at $162,567 at a California clinic, despite Merck's list price of $24,000. The drug generated $31.7 billion in worldwide sales in 2025, representing nearly half of Merck's revenue. A joint investigation by the International Consortium of Investigative Journalists and USA TODAY found Merck employs multiple tactics to maintain high prices, including building patent walls against generic competition, lobbying against Medicare price negotiations, and maintaining higher dosing despite studies suggesting weight-based dosing would be effective and cheaper. Whilst Merck CEO Robert Davis pledged support for President Trump's drug pricing initiatives in December, he made no commitments regarding Keytruda. Merck attributes US price inflation to pharmacy benefit managers and insurers who add fees and rebates.

Longevity.Technology
Apr 9th, 2026
Merck bets $838M on antibody startup Infinimmune for faster drug discovery

Merck has announced a collaboration with Infinimmune, a California-based biotech founded in 2022, worth up to $838 million to discover new antibody drug candidates. The deal targets multiple undisclosed targets selected by Merck, though upfront payment details were not disclosed. Infinimmune's platform identifies promising antibodies by studying memory B cells from the human immune system. The company claims it can identify antibodies binding to a target within one week and prepare candidates for animal studies in roughly three months. Chief executive Wyatt McDonnell described the approach as building a massive database of immune cell information that can be searched for matching antibodies. The 10-person startup is also developing IFX-101, its lead candidate for moderate-to-severe atopic dermatitis, designed for quarterly or twice-yearly dosing.

Yahoo Finance
Apr 7th, 2026
JPMorgan raises Merck price target to $135 as EU approves KEYTRUDA for ovarian cancer

Merck & Co. (NYSE: MRK) received a price target increase from JPMorgan to $135 from $125 on 6 April, maintaining an Overweight rating ahead of its 30 April earnings report. The firm highlighted Merck's pipeline as the primary focus, citing a favourable risk-return setup with key data readouts expected in 2026 and 2027. On 2 April, Merck announced EU approval for KEYTRUDA combined with paclitaxel for adults with platinum-resistant ovarian, fallopian tube or primary peritoneal carcinoma. The approval marks the first PD-1 inhibitor-based option for eligible patients with platinum-resistant ovarian cancer in the EU and extends across all 27 member states plus Iceland, Liechtenstein and Norway.

Ophthalmology Times
Apr 7th, 2026
Merck launches phase 2b/3 MALBEC trial of MK-8748 in wet AMD.

Merck launches phase 2b/3 MALBEC trial of MK-8748 in wet AMD. MALBEC (NCT07440225) is a randomized, double-masked trial evaluating the safety and efficacy of MK-8748 at 2 dose levels versus control (aflibercept 2mg). Merck has initiated MALBEC, its phase 2b/3 clinical trial evaluating MK-8748 (also known as Tiespectus, EYE201) for the treatment of neovascular (wet) age-related macular degeneration (AMD). MK-8748 is defined by the company as a "novel investigational bispecific antibody with a dual mechanism that directly activates the Tie2 pathway and inhibits VEGF with the goal of stabilizing retinal and choroidal blood vessels and reducing fluid accumulation in the macula." According to the company, preclinical evidence may suggest that dual pathway modulation helps improve vascular stability in the retina and supports vision preservation in patients with certain vascular retinal diseases.[1] MALBEC is a randomized, double-masked trial evaluating the safety and efficacy of MK-8748 at 2 dose levels versus control (aflibercept 2mg). The primary endpoint of the trial is mean change in best-corrected visual acuity (BCVA) from baseline to Year 1 in the study eye of the participants, using standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) vision. Patients will be randomized 1:1:1 to receive 2 dose regimens of MK-8748 or aflibercept 2mg. Patients will initially receive 3 monthly doses of MK-8748 or aflibercept 2mg. These doses will be followed by treatments every 8 weeks until week 48. Following week 48, patients will be treated at intervals determined based on individualized response to treatment, with the last study visit at week 96. David Guyer, MD, founder, CEO and president of, commented on the trial in a press release from the company, saying, "Despite available therapies, many patients with neovascular age-related macular degeneration remain at risk of further vision loss due to continued vascular leakage. With its differentiated dual mechanism directly agonizing Tie2 and inhibiting VEGF, MK-8748 has the potential to offer a novel approach to maintain vascular stability for patients with serious retinal diseases." In addition to MALBEC, the company intends to initiate a second study in wet AMD in 2026. The company noted that the plan to advance into pivotal studies is based on results from the Phase 1/2a RIOJA trial, which was a 2-part study evaluating MK-8748 in patients with either wet AMD, macular edema secondary to branch retinal vein occlusion (BRVO), or diabetic macular edema (DME). In addition to MK-8748, Merck is developing MK-3000 (also known as Restoret, EYE103) for the treatment of DME. MK-3000 is currently being evaluated in the BRUNELLO trial, a randomized, double-masked trial evaluating the efficacy and safety of 2 dose levels of intravitreal MK-3000 versus active control ranibizumab.[2] References: Don't miss out - get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

INACTIVE